Appointment strengthens leadership team as company expands access to its endoscopic treatment for obesity and type 2 diabetes.

Morphic Medical has appointed Jane Wright as chief financial officer as it continues the European rollout of Reset, its endoscopic non-surgical treatment for obesity and type 2 diabetes.

Wright has more than 30 years of experience in senior financial and operational roles across international medical device companies, focusing on complex regulatory environments and international growth. She previously served as finance and operations director at Apollo Endosurgery, which was acquired by Boston Scientific in 2022.

Her arrival follows the appointment of Mike Gutteridge as chief executive in July and marks another step in building out Morphic Medical’s senior team.

The company recently received CE mark certification and commercial registration from the UK Medicines and Healthcare products Regulatory Agency, clearing Reset for sale in key European markets. Rollout has already begun in Germany. Research presented at the IFSO World Congress of obesity experts this month showed that patients treated with Reset lost an average of 18.9% of their total body weight, alongside improvements in blood sugar control.

In her new role, Wright will shape Morphic’s long-term financial strategy and support its international expansion.

Mike Gutteridge, president and chief executive of Morphic Medical, said: “We are thrilled to welcome Jane to our executive team. Her extensive expertise and deep knowledge of the sector makes her a real asset to Morphic as the momentum within the business continues to build.”

Jane Wright, chief financial officer of Morphic Medical, added: “I’m joining Morphic Medical at an exciting time in its growth journey. I look forward to working closely with the leadership team to help take the business to the next level.”